๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

A Study of GR1803 in Systemic Lupus Erythematosus

RecruitingPhase 1, Phase 2Ages 18 Years - 60 YearsAllGenrix (Shanghai) Biopharmaceutical Co., Ltd.
NCT07348055 on ClinicalTrials.gov โ†—
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

to evaluate the safety and efficacy of GR1803 in the treatment of patients with systemic lupus erythematosus

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * comfirmed diagnosis of systemic lupus erythematosus * SLEDAI-2Kโ‰ฅ6ๅˆ† * written informed consent and ability to comply with protocol requirements * have received adequate dose of glucocorticoids, antimalarials, immunosuppressants for 3 months Exclusion Criteria: * with unstable acute and chronic diseases * active infection * history of malignant tumor within 5 years
๐Ÿ’Š

What it tests

  • GR1803 injection
๐Ÿ“

Where

1 site
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, China
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy